HFpEF Pharmacological Management

Practice‑Changing Therapies for HFpEF/HFmrEF: SGLT2i, MRAs and Incretin Trials

Harriette Van Spall, Maja Cikes

Watch time: 22m 28s

Hugo Prado-Prado, Sergio Raposeiras-Roubín

Read time: 8m 20s

Dominic Marcel Alfonso

Read time: 15m

Magdy Abdelhamid , Mostafa M Abdrabou, Emanuel Faris, et al

Read time: 16m
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF

Barry Borlaug

Watch time: 7m 15s
Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows

Radcliffe CVRM

ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function

Safia Chatur

Watch time: 5m 49s
Study Finds Multimorbidity Dramatically Increases Mortality Risk in Heart Failure Patients with Mildly Reduced and Preserved Ejection Fraction

Radcliffe CKM

THT 2025: The SUMMIT Trial

Barry Borlaug

Watch time: 6m 31s
AHA 24: The EMPEROR-Preserved Trial

Andrew JS Coats

Watch time: 4m 41s
AHA 24 Late-Breaking Discussion: The SUMMIT Trial

Harriette Van Spall, Milton Packer

Watch time: 17m 22s

Aleksandra Bykova, Maria Serova, Maria Chashkina, et al

Read time: 22m 11s
Practice‑Changing Therapies for HFpEF/HFmrEF: SGLT2i, MRAs and Incretin Trials

Harriette Van Spall, Maja Cikes

Watch time: 22m 28s

Magdy Abdelhamid , Mostafa M Abdrabou, Emanuel Faris, et al

Read time: 16m

Giulio Balestrieri, Raul Limonta, Enrico Ponti, et al

Read time: 18m 10s
ACC.24: The STEP HFpEF DM Trial

Mikhail Kosiborod

Watch time: 6m 41s

Dominic Marcel Alfonso

Read time: 15m

Hugo Prado-Prado, Sergio Raposeiras-Roubín

Read time: 8m 20s
Study Finds Multimorbidity Dramatically Increases Mortality Risk in Heart Failure Patients with Mildly Reduced and Preserved Ejection Fraction

Radcliffe CKM

Aleksandra Bykova, Maria Serova, Maria Chashkina, et al

Read time: 22m 11s
ESC 23 Late-Breaker Discussion: The STEP HFpEF Trial

Harriette Van Spall, Mikhail Kosiborod

Watch time: 13m 24s
2023 ESC Guidelines Update: Acute & Chronic Heart Failure

Giuseppe Rosano, Harriette Van Spall

Watch time: 10m 8s
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF

Barry Borlaug

Watch time: 7m 15s
AHA 24 Late-Breaking Discussion: The SUMMIT Trial

Harriette Van Spall, Milton Packer

Watch time: 17m 22s

Media

Practice‑Changing Therapies for HFpEF/HFmrEF: SGLT2i, MRAs and Incretin Trials

Harriette Van Spall, Maja Cikes

Watch time: 22m 28s
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF

Barry Borlaug

Watch time: 7m 15s
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function

Safia Chatur

Watch time: 5m 49s
THT 2025: The SUMMIT Trial

Barry Borlaug

Watch time: 6m 31s
AHA 24: The EMPEROR-Preserved Trial

Andrew JS Coats

Watch time: 4m 41s
AHA 24 Late-Breaking Discussion: The SUMMIT Trial

Harriette Van Spall, Milton Packer

Watch time: 17m 22s
ESC 24: MRAs in Heart Failure

Watch time: 5m 46s

Muthiah Vaduganathan,

Broadcast

Heart Failure
Medical Options for Advanced HFpEF/HFmrEF Patients

Biykem Bozkurt, Pardeep Jhund, Muthiah Vaduganathan

Watch time: 1h 1m 12s
HFA 24 Late-Breaker Discussion: Insights from the STEP-HFpEF

Harriette Van Spall, Mikhail Kosiborod

Watch time: 12m 4s
ACC.24: The STEP HFpEF DM Trial

Mikhail Kosiborod

Watch time: 6m 41s
2023 ESC Guidelines Update: Acute & Chronic Heart Failure

Giuseppe Rosano, Harriette Van Spall

Watch time: 10m 8s

Articles

SGLT2 Inhibitors in Acute Heart Failure

Hugo Prado-Prado

,

Sergio Raposeiras-Roubín

,

Published:

02 March 2026

Citation:

European Cardiology Review 2026;21:e11.

DOI:

https://doi.org/10.15420/ecr.2025.70
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Downloads: Downloads 78
  • Read time: 8m 20s

Apelin/APJ and Incretin Therapy in Heart Failure

Dominic Marcel Alfonso

,

Published:

19 February 2026

Citation:

Cardiac Failure Review 2026;12:e03.

DOI:

https://doi.org/10.15420/cfr.2025.54
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Downloads: Downloads 22
  • Read time: 15m

GLP-1RAs: Mechanism of Action and Role in HFpEF Management

Magdy Abdelhamid

,

Mostafa M Abdrabou

,

Emanuel Faris

,

Sameh El Kafas

,

Mohamed Hosny

,

Ahmed Hassan

,

Published:

03 November 2025

Citation:

Cardiac Failure Review 2025;11:e28.

DOI:

https://doi.org/10.15420/cfr.2025.17
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Downloads: Downloads 224
  • Citations: 6
  • Read time: 16m

GLP-1RA in Different HFpEF Phenotypes

Aleksandra Bykova

,

Maria Serova

,

Maria Chashkina

,

Raisa Kosharnaya

,

Zukhra Salpagarova

,

Denis Andreev

,

Ilya Giverts

,

Published:

16 October 2024

Citation:

Cardiac Failure Review 2024;10:e14.

DOI:

https://doi.org/10.15420/cfr.2024.06
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Downloads: Downloads 226
  • Citations: 10
  • Read time: 22m 11s